AstraZeneca's Imfinzi misses main goal of advanced lung cancer study

London-listed drugmaker AstraZeneca Plc said on Wednesday its immunotherapy treatment Imfinzi did not meet the main goal of a late-stage study for advanced non-small cell lung cancer.